Form 8-K - Current report:
SEC Accession No. 0000318154-22-000005
Filing Date
2022-02-07
Accepted
2022-02-07 16:16:56
Documents
15
Period of Report
2022-02-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amgn-20220207.htm   iXBRL 8-K 55720
2 EX-99.1 amgenq42021earningsrelease.htm EX-99.1 681533
3 GRAPHIC amgenlogoa14.jpg GRAPHIC 6206
  Complete submission text file 0000318154-22-000005.txt   990700

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amgn-20220207.xsd EX-101.SCH 3091
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT amgn-20220207_def.xml EX-101.DEF 17327
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amgn-20220207_lab.xml EX-101.LAB 33559
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amgn-20220207_pre.xml EX-101.PRE 17615
9 EXTRACTED XBRL INSTANCE DOCUMENT amgn-20220207_htm.xml XML 14887
Mailing Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320
Business Address ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 (805)447-1000
AMGEN INC (Filer) CIK: 0000318154 (see all company filings)

EIN.: 953540776 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37702 | Film No.: 22597564
SIC: 2836 Biological Products, (No Diagnostic Substances)